SeaStar Medical Holding (Nasdaq:ICU) - Aandelenkoers, Nieuws & Analyse

ICU Overzicht aandelen

ICU fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 176.26% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $68K )

Negatief eigen vermogen

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft minder dan 1 jaar cash runway

+ 3 meer risico's

SeaStar Medical Holding Corporation Concurrenten

Beyond Air

NasdaqCM:XAIR

US$39.0m

PetVivo Holdings

OTCPK:PETV

US$10.8m

Lifeward

NasdaqCM:LFWD

US$16.8m

Sintx Technologies

NasdaqCM:SINT

US$6.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor SeaStar Medical Holding
Historische aandelenkoersen
Huidige aandelenkoers	US$2.05
52 Week Hoogtepunt	US$42.92
52 Week Laag	US$1.83
Bèta	-1.06
11 maand verandering	-42.58%
3 maanden verandering	-64.10%
1 Jaar Verandering	-77.90%
33 jaar verandering	-99.18%
5 jaar verandering	n/a
Verandering sinds IPO	-99.16%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	ICU	US Medical Equipment	US Markt
7D	-6.4%	1.5%	2.2%
1Y	-77.9%	20.8%	31.6%

Rendement versus industrie: ICU presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 20.8 % opleverde.

Rendement versus markt: ICU presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is ICU's price volatile compared to industry and market?
ICU volatility
ICU Average Weekly Movement	11.8%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van ICU is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ICU is het afgelopen jaar gedaald van 21% naar 12%, maar is nog steeds hoger dan 75% van de US -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	12	Eric Schlorff	www.seastarmedical.com

SeaStar Medical Holding Corporation, een bedrijf voor medische hulpmiddelen, ontwikkelt een platformtherapie om de gevolgen van hyperinflammatie op vitale organen in de Verenigde Staten te verminderen. Het bedrijf biedt ontstekingsreacties om infecties af te weren en beschadigd weefsel in het lichaam te herstellen. Het ontwikkelt ook producten in verschillende therapeutische gebieden, waaronder acute nierschade bij kinderen en volwassenen op CRRT; cardiorenaal syndroom bij congestief hartfalen; myocardiale bedwelming bij nierziekte in het eindstadium; en hepatorenaal syndroom.

SeaStar Medical Holding Corporation Samenvatting

Hoe verhouden de winst en inkomsten van SeaStar Medical Holding zich tot de beurswaarde?
ICU fundamentele statistieken
Marktkapitalisatie	US$8.94m
Inkomsten(TTM)	-US$29.67m
Inkomsten(TTM)	US$68.00k

131.5x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is ICU overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ICU resultatenrekening (TTM)
Inkomsten	US$68.00k
Kosten van inkomsten	US$0
Brutowinst	US$68.00k
Overige uitgaven	US$29.74m
Inkomsten	-US$29.67m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-6.80
Brutomarge	100.00%
Nettowinstmarge	-43,638.24%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ICU op de lange termijn?

Bekijk historische prestaties en vergelijking

ICU Overzicht aandelen

Beloningen

Risicoanalyse

SeaStar Medical Holding Corporation Concurrenten

NasdaqCM:XAIR

US$39.0m

OTCPK:PETV

US$10.8m

NasdaqCM:LFWD

US$16.8m

NasdaqCM:SINT

US$6.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

FDA Grants Breakthrough Device Designation for Seastar Medical’S Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Holding Corporation Announces Record Monthly Enrollment Achieve in It's Pivotal Adult AKI Trial

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Seastar Medical Holding Corporation Announces Enrollment in Its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $25 million.

Levi & Korsinsky, LLP Notifies Investors in Seastar Medical Holding Corporation of A Class Action Securities Lawsuit

Recent updates

FDA Grants Breakthrough Device Designation for Seastar Medical’S Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Holding Corporation Announces Record Monthly Enrollment Achieve in It's Pivotal Adult AKI Trial

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Seastar Medical Holding Corporation Announces Enrollment in Its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $25 million.

Levi & Korsinsky, LLP Notifies Investors in Seastar Medical Holding Corporation of A Class Action Securities Lawsuit

SeaStar Medical Holding Corporation Announces First Pediatric Patient Treated in A Commercial Setting with FDA-Approved QUELIMMUNE Therapeutic Device

SeaStar Medical Holding Corporation has completed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

The Schall Law Firm Reminds Class Action Lawsuit Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Corporation Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device

High number of new and inexperienced directors

SeaStar Medical Holding Announces Compliance Update with Nasdaq Listing Rule 5550(b)(2) and Nasdaq Listing Rule 5550(a)(2)

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Holding Corporation announced delayed annual 10-K filing

Seastar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

FDA Grants Humanitarian Device Exemption Approval to Seastar Medical’S Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department Regarding the Company Regains Compliance with the Market Value Rule

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Holding Receives Non-Compliance Notice from Nasdaq

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

New major risk - Shareholder dilution

U.S. Food and Drug Administration Issues Approvable Letter for SeaStar Medical Holding Corporation's Selective Cytopheretic Device for Pediatric Patients

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

SeaStar Medical Holding Corporation Announces Publication of Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with it's Selective Cytopheretic Device

SeaStar Medical Holding Corporation Enrolls First Patient in NEUTRALIZE-AKI Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

Seastar Medical Holding Receives Nasdaq Staff Deficiency Letter Regarding Non-Compliance with Market Value of Listed Securities Requirements

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 28, 2023

SeaStar Medical Holding Corporation Provides Regulatory Update Related to HDE Application for Pediatric Selective Cytopheretic Device

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury

Seastar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Submits Investigational Device Exemption Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

High number of new directors

Seastar Medical Appoints Rick Barnett as Chairman of the Board of Directors

No independent directors

SeaStar Medical Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

SeaStar Medical Holding Corporation Samenvatting

131.5x

-0.3x

Inkomsten en omzet